[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100445483":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":35,"centralContacts":10,"locations":39,"responsibleParty":74,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":10,"eligibilityCriteria":86,"healthyVolunteers":83,"sex":87,"minAge":88,"maxAge":10,"enrollmentInfo":89,"targetDuration":10,"studyType":92,"phases":10,"briefSummary":93,"conditions":94,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"OHSU Knight Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (biospecimen collection, medical record review)",null,"Patients undergo collection of blood samples at baseline (before any neoadjuvant therapy), every 2 months while undergoing TNT, and then every 3 months for up to 3 years after completion of TNT. Patients' medical records are also reviewed. Patients may undergo collection of tissue sample if an archival tissue sample is not available.",[13,14,15],"Procedure: Biopsy","Procedure: Biospecimen Collection","Other: Electronic Health Record Review",[17,25,31],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"PROCEDURE","Biopsy","Undergo biopsy",[9],[23,24],"BIOPSY_TYPE","Bx",{"type":18,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Biospecimen Collection","Undergo collection of blood and\u002For tissue samples",[9],[30],"Biological Sample Collection",{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Electronic Health Record Review","Medical records are reviewed",[9],[36],{"name":37,"affiliation":5,"role":38},"Adel Kardosh, M.D.,Ph.D.","PRINCIPAL_INVESTIGATOR",[40,59],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Portland","Oregon","97239","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-122.67621,45.52345,{"lat":51,"lon":50},[54,58],{"name":37,"role":55,"phone":56,"phoneExt":10,"email":57},"CONTACT","503-494-5207","kardosh@ohsu.edu",{"name":37,"role":38,"phone":10,"phoneExt":10,"email":10},{"facility":60,"status":41,"city":61,"state":62,"zip":63,"country":45,"countryCode":46,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Fred Hutch","Seattle","Washington","98109",{"type":48,"coordinates":65},[66,67],-122.33207,47.60621,{"lat":67,"lon":66},[70],{"name":71,"role":55,"phone":72,"phoneExt":10,"email":73},"Stacey Cohen, MD","206-606-6658","shiovitz@uw.edu",{"type":38,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Adel Kardosh M.D., Ph.D.","Principal Investigator",[78],{"name":79,"class":80},"Natera, Inc.","INDUSTRY","100445483","establishing-a-ctdna-biomarker-to-improve-organ-preserving-strategies-in-patients-with-rectal-cancer-100445483",false,"NCT05081024","Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer","Inclusion Criteria:\n\n* Participant must provide written informed consent before any study-specific procedures or interventions are performed\n* Participants aged \\>= 18 years\n* Pathologically-confirmed stage II or III primary adenocarcinoma of the rectum:\n\n  * T3N0M0 - T4bN2M0\n\nExclusion Criteria:\n\n* Has radiologic evidence of distant metastases at the time of screening\u002Fenrollment\n* Has received prior treatment for their rectal adenocarcinoma\n* Requires or has received blood transfusion within 1 month of study enrollment","ALL","18 Years",{"count":90,"type":91},50,"ESTIMATED","OBSERVATIONAL","This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.",[95,96,97,98,99,100,101,102,103],"Rectal Adenocarcinoma","Stage II Rectal Cancer AJCC v8","Stage IIA Rectal Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage IIC Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","2025-09-24",{"date":106,"type":107},"2025-09-25","ACTUAL",{"date":109,"type":107},"2021-09-03",{"date":111,"type":91},"2026-09-03",{"name":5,"class":6},2]